文献速递生殖医学

预测多个完整体外受精周期累积活产几率:一项外部验证研究

Predicting the cumulative chance of live birth over multiple complete cycles of in vitro fertilization: an external validation study.
PubMed 文献 · Hum Reprod · 2018-01-01

本研究在1515名荷兰女性的独立前瞻性队列中外部验证McLernon模型,预测多个完整IVF周期的累积活产率。治疗前模型c统计量为0.62,校准后略微高估;治疗后模型c统计量为0.71,校准准确。加入AMH、AFC和体重后,更新版治疗前模型c统计量提高至0.66,治疗后模型保持在0.71。

要点

  • 治疗前模型c统计量0.62,校准后略微高估累积活产率。
  • 治疗后模型c统计量0.71,校准图显示预测准确。
  • 加入AMH、AFC和体重后,更新版治疗前模型c统计量提高至0.66。

核心结论

  • 经过小幅重新校准,两个McLernon模型均能在不同地理背景和较近时间段准确预测累积活产率。

研究设计与样本

  • 外部验证研究,纳入1515名荷兰女性,2011年至2014年间接受首次IVF治疗,共2881个完整治疗周期。
  • 完整周期定义为一次卵巢刺激产生的所有新鲜和冻融胚胎移植,随访18个月,主要结局为导致活产的持续妊娠。

主要发现

  • 治疗前模型c统计量为0.62(95%CI:0.59-0.64),治疗后模型为0.71(95%CI:0.69-0.74)。
  • 治疗前模型校准图显示略微高估累积活产率,通过截距减去0.35重新校准。
  • 治疗后模型校准图显示准确的累积活产率预测。
  • 加入AMH、AFC和体重后,更新版治疗前模型c统计量略微提高至0.66(95%CI:0.64-0.68),更新版治疗后模型保持在0.71(95%CI:0.69-0.73)。

关键数值与推荐

  • 使用重新校准的治疗前模型,30岁、原发性不孕2年、因男性因素开始ICSI治疗的女性,第一个完整周期活产几率为40%,三个完整周期增至72%。
  • 若该女性体重70 kg、AMH 1.5 ng/mL、AFC 10,更新版治疗前模型将第一个完整周期活产几率修正为30%,三个完整周期为59%。
  • 若该女性第一个ICSI周期获卵5枚、无胚胎冷冻、移植一枚新鲜卵裂期胚胎,治疗后模型估计活产几率分别为28%和58%。

临床怎么用

  • 经过全国性重新校准以考虑IVF治疗的地理差异后,McLernon预测模型可作为新的咨询工具引入临床实践,以告知患者并补充临床推理。

局限性

  • OPTIMIST研究嵌套了两项随机对照试验(RCT),评估基于AFC的促性腺激素剂量个体化效果。
  • 严格的给药方案、RCT的纳入和排除标准以及18个月的有限随访时间可能影响了模型在该独立队列中的性能。
  • 与原始模型开发研究一致,外部验证使用了乐观假设,即未活产而停止治疗的夫妇的累积活产率与继续治疗者相同。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Are the published pre-treatment and post-treatment McLernon models, predicting cumulative live birth rates (LBR) over multiple complete IVF cycles, valid in a different context? SUMMARY ANSWER: With minor recalibration of the pre-treatment model, both McLernon models accurately predict cumulative LBR in a different geographical context and a more recent time period. WHAT IS KNOWN ALREADY: Previous IVF prediction models have estimated the chance of a live birth after a single fresh embryo transfer, thereby excluding the important contribution of embryo cryopreservation and subsequent IVF cycles to cumulative LBR. In contrast, the recently developed McLernon models predict the cumulative chance of a live birth over multiple complete IVF cycles at two certain time points: (i) before initiating treatment using baseline characteristics (pre-treatment model) and (ii) after the first IVF cycle adding treatment related information to update predictions (post-treatment model). Before implementation of these models in clinical practice, their predictive performance needs to be validated in an independent cohort. STUDY DESIGN, SIZE, DURATION: External validation study in an independent prospective cohort of 1515 Dutch women who participated in the OPTIMIST study (NTR2657) and underwent their first IVF treatment between 2011 and 2014. Participants underwent a total of 2881 complete treatment cycles, with a complete cycle defined as all fresh and frozen thawed embryo transfers resulting from one episode of ovarian stimulation. The follow up duration was 18 months after inclusion, and the primary outcome was ongoing pregnancy leading to live birth. PARTICIPANTS/MATERIALS, SETTING, METHODS: Model performance was externally validated up to three complete treatment cycles, using the linear predictor as described by McLernon et al. to calculate the probability of a live birth. Discrimination was expressed by the c-statistic and calibration was depicted graphically in a calibration plot. In contrast to the original model development cohort, anti-Müllerian hormone (AMH), antral follicle count (AFC) and body weight were available in the OPTIMIST cohort, and evaluated as potential additional predictors for model improvement. MAIN RESULTS AND THE ROLE OF CHANCE: Applying the McLernon models to the OPTIMIST cohort, the c-statistic of the pre-treatment model was 0.62 (95% CI: 0.59-0.64) and of the post-treatment model 0.71 (95% CI: 0.69-0.74). The calibration plot of the pre-treatment model indicated a slight overestimation of the cumulative LBR. To improve calibration, the pre-treatment model was recalibrated by subtracting 0.35 from the intercept. The post-treatment model calibration plot revealed accurate cumulative LBR predictions. After addition of AMH, AFC and body weight to the McLernon models, the c-statistic of the updated pre-treatment model improved slightly to 0.66 (95% CI: 0.64-0.68), and of the updated post-treatment model remained at the previous level of 0.71 (95% CI: 0.69-0.73). Using the recalibrated pre-treatment model, a woman aged 30 years with 2 years of primary infertility who starts ICSI treatment for male factor infertility has a chance of 40% of a live birth from the first complete cycle, increasing to 72% over three complete cycles. If this woman weighs 70 kg, has an AMH of 1.5 ng/mL and an AFC of 10 measured at the beginning of her treatment, the updated pre-treatment model revises the estimated chance of a live birth to 30% in the first complete cycle and 59% over three complete cycles. If this woman then has five retrieved oocytes, no embryos cryopreserved and a single fresh cleavage stage embryo transfer in her first ICSI cycle, the post-treatment model estimates the chances of a live birth at 28 and 58%, respectively. LIMITATIONS, REASONS FOR CAUTION: Two randomized controlled trials (RCT) evaluating the effectiveness of gonadotropin dose individualization on basis of the AFC were nested within the OPTIMIST study. The strict dosing regimens, the RCT in- and exclusion criteria and the limited follow up time of 18 months might have influenced model performance in this independent cohort. Also, consistent with the original model development study, external validation was performed using the optimistic assumption that the cumulative LBR in couples who discontinue treatment without a live birth would have been equal to that of those who continue treatment. WIDER IMPLICATIONS OF THE FINDINGS: After national recalibration to account for geographical differences in IVF treatment, the McLernon prediction models can be introduced as new counselling tools in clinical practice to inform patients and to complement clinical reasoning. These models are the first to offer an objective and personalized estimate of the cumulative probability of a live birth over multiple complete IVF cycles. STUDY FUNDING/COMPETING INTEREST(S): No external funds were obtained for this study. M.J.C.E., D.J.M. and S.B. have nothing to disclose. J.A.L, S.C.O, T.C.v.T. and H.LT. received an unrestricted personal grant from Merck BV. B.W.M. is supported by a NHMRC Practitioner Fellowship (GNT1082548) and reports consultancy for ObsEva, Merck and Guerbet. F.J.M.B. receives monetary compensation as a member of the external advisory board for Merck BV (the Netherlands) and Ferring pharmaceutics BV (the Netherlands), for consultancy work for Gedeon Richter (Belgium) and Roche Diagnostics on automated AMH assay development, and for a research cooperation with Ansh Labs (USA). TRIAL REGISTRATION NUMBER: Not applicable.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Leijdekkers JA, Eijkemans MJC, van Tilborg TC, et al. Predicting the cumulative chance of live birth over multiple complete cycles of in vitro fertilization: an external validation study. Hum Reprod. 2018. PMID: 30085143. doi:10.1093/humrep/dey263

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。